MeiraGTx
MeiraGTx's revenue rose 144.6% to $81 million in fiscal 2025. Its operating margin was −130.2%, up from −493.4% a year earlier. Free cash flow was −$50 million. The diluted share count rose 15.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What MeiraGTx does
MeiraGTx is a clinical-stage genetic medicines company, meaning its medicines are still being tested in people. Its programs give small doses of genetic medicine directly to the affected part of the body. Late-stage programs include dry mouth caused by radiation treatment, Parkinson's disease and an inherited eye disease linked to the AIPL1 gene.
It makes its own medicines. It owns two viral vector factories, in London and Shannon, Ireland, plus its own plasmid production and quality control. A viral vector is a harmless virus used to carry genes into cells. In December 2025 UK regulators gave its London plant a commercial manufacturing authorization. It supplies product to others under supply agreements.
MeiraGTx also developed a gene-control technology, built on molecules called riboswitches, that lets an oral small-molecule pill turn a gene's output up or down. It is applying this to metabolic hormones such as GLP-1, to cell therapy and to chronic pain. It has sold a program under an asset purchase agreement that could bring milestone payments, and it is reviewing strategic transactions.
Its biggest risks, as it describes them
- It has lost money since it started and may never be profitable.
- It may not receive the milestone payments or commercial supply revenue it expects from an asset sale and supply agreement.
- It needs additional capital, and may struggle to meet debt obligations and covenants.
- It depends on the success of product candidates still in development.
- Gene therapy is new, so the rules and the time and cost to win approval are uncertain.
Income statement
MeiraGTx lost money in fiscal 2025: a net loss of $114 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 138 | 116 | 130 | 104 | 66 |
| Debt incl. finance leases | — | 71 | 72 | 73 | 74 |
| Net debt (negative means net cash) | — | −44 | −58 | −30 | 9 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.6x | 0.5x | 1.1x | — |
| Interest coverage | −252.6x | −23.5x | −10.3x | −12.4x | −8.7x |
| Current ratio | 2.7x | 1.9x | 2.4x | 2.0x | 0.8x |
| Quick ratio | 2.7x | 1.9x | 2.4x | 2.0x | 0.8x |
Cash flow
Projections
Project MeiraGTx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of MeiraGTx reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 2 of 8 | 3 of 8 |
| Rule of 40 | −907.6% | −191.5% | 82.9% |
| Altman Z'' | −5.72 | −10.70 | −14.65 |
| Accruals ratio | 6.6% | −14.5% | −26.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 2 of 8 | 2 of 8 | 3 of 8 |
Compare
Put MeiraGTx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| MeiraGTx | FY25 | 144.6% | −130.2% | −61.7% | — | — | 3 | |
| 4D Molecular Therapeutics | FY25 | 230,194.6% | −187.2% | −128.7% | — | — | — | Compare |
| CytomX Therapeutics | FY25 | −44.8% | −29.4% | −99.5% | — | — | — | Compare |
| Cytokinetics | FY25 | 376.6% | −695.4% | −607.5% | — | — | — | Compare |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | 13 | 16 | 38 | 16 | 14 | 33 | 81 |
| Revenue growth | — | — | — | 17.1% | 142.2% | −57.8% | −11.9% | 137.4% | 144.6% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 22 | 34 | 25 | 34 | 67 | 86 | 104 | 120 | 130 |
| Operating income | −32 | −78 | −58 | −63 | −73 | −116 | −137 | −164 | −106 |
| Net income | −31 | −83 | −55 | −58 | −80 | −130 | −84 | −148 | −114 |
| Diluted EPS (US$) | −3.72 | −4.47 | −1.65 | −1.54 | −1.80 | −2.87 | −1.49 | −2.12 | −1.42 |
| Diluted shares (millions) | 9 | 19 | 33 | 38 | 44 | 45 | 56 | 70 | 80 |
| Cash flow | |||||||||
| Cash from operations | −18 | −59 | 20 | −64 | −10 | −73 | −105 | −104 | −46 |
| Capital expenditure | 10 | 11 | 9 | 21 | 46 | 45 | 20 | 5 | 4 |
| Free cash flow | −29 | −70 | 11 | −85 | −57 | −118 | −126 | −109 | −50 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 18 | 16 | 18 | 21 | 29 | 28 | 25 | 22 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 8 | 68 | 227 | 210 | 138 | 116 | 130 | 104 | 66 |
| Debt incl. finance leases | — | — | — | — | — | 71 | 72 | 73 | 74 |
| Total assets | 26 | 97 | 324 | 364 | 320 | 318 | 327 | 270 | 244 |
| Total liabilities | 22 | 16 | 133 | 125 | 135 | 200 | 189 | 202 | 250 |
| Shareholders' equity | −47 | 81 | 191 | 239 | 185 | 118 | 138 | 68 | −6 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | −438.4% | −401.9% | −193.0% | −730.9% | −977.8% | −493.4% | −130.2% |
| Net margin | — | — | −411.9% | −372.6% | −211.0% | −814.2% | −599.5% | −444.1% | −140.3% |
| Free cash flow margin | — | — | 83.2% | −545.5% | −150.9% | −741.6% | −895.6% | −328.9% | −61.7% |
| Rule of 40 (growth + FCF margin) | — | — | — | −528.4% | −8.6% | −799.4% | −907.6% | −191.5% | 82.9% |
| Return on capital | — | — | — | — | — | — | −140.6% | −219.7% | — |
| Return on equity | — | −491.9% | −40.3% | −27.0% | −37.5% | −85.5% | −65.7% | −143.5% | −368.2% |
| Return on assets | — | −135.0% | −26.0% | −16.9% | −23.3% | −40.6% | −26.1% | −49.5% | −44.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |